Business Objectives Changed

The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).

Inclusion Criteria (Cohort #1):

• Diagnosis of B-CLL by NCI criteria
• Require chemotherapy and have fully recovered from previous administered chemotherapy
• Subjects must have progressed, failed to achieve a meaningful response, or relapsed/intolerant to prior therapy. Failing at least one purine analogue regimen
• Subjects have received three or fewer prior treatment regimens
• ECOG status of 0 - 2

Inclusion Criteria (Cohort #2):

• If dose level + 3 is reached, the criteria is the same as outlined for Cohort #1, however the subjects should not have a history of prior chemotherapy (treatment naive)

Exclusion Criteria:

• Unwilling or unable to use an acceptable method to avoid pregnancy
• Uncontrolled or significant cardiovascular disease, including prolonged QTc interval
• History of significant bleeding disorder, unrelated to CLL
• Prior concurrent malignancy
• Drugs that generally accepted to have the risk of causing Torsades de Pointes
• Autoimmune hemolytic anemia requiring therapy or transfusion support
• Autoimmune thrombocytopenia requiring steroid therapy or transfusion support
• Richter's Syndrome
• Transformation to prolymphocytic leukemia